Glabellar Frown Lines Clinical Trial
Official title:
A Prospective, Multicenter, Randomized, Rater- and Subject-Blind, Parallel Group Trial to Investigate the Non-Inferiority of NT 201, Free of Complexing Proteins, in Comparison With Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines
NT 201, also known as IncobotulinumtoxinA (Xeomin®/Bocouture®), is a Botulinum toxin type A preparation free of complexing proteins (150 kiloDalton). Injected into the muscle, NT201 causes a reversible local relaxation of the injected muscle. Botulinum toxin type A is used for aesthetic treatment of mimic wrinkles and in the therapy of neurologic diseases. This study will investigate the safety and efficacy (non-inferiority) of NT 201 in comparison with OnabotulinumtoxinA (Vistabel®) in the treatment of glabellar frown lines.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02236312 -
Safety and Efficacy Study of Botulinum Toxin for the Treatment of Glabellar Frown Lines
|
Phase 2 | |
| Active, not recruiting |
NCT05565950 -
AI-09 In Subjects With Glabellar Lines, GL-101
|
Phase 1/Phase 2 | |
| Completed |
NCT00430963 -
IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines
|
Phase 3 | |
| Recruiting |
NCT05083286 -
Duration of Botox Using OLD Versus COLD for Treatment of Glabellar Lines
|
Early Phase 1 | |
| Completed |
NCT03687736 -
Subject Satisfaction With AbobutulinumtoxinA Treatment
|
Phase 4 | |
| Active, not recruiting |
NCT04281745 -
Long-term Open-label Treatment of Moderate to Severe Glabellar Lines With CORETOX®
|
Phase 4 | |
| Active, not recruiting |
NCT05623410 -
Study to Compare the Efficacy and Safety of ATGC-110 (Botulinum Toxin) With Xeomin® for the Treatment of Moderate to Severe Glabellar Frown Lines
|
Phase 3 | |
| Active, not recruiting |
NCT03440671 -
The Safety and Efficacy Study of Hutox Versus Botox® in Subject With Moderate to Severe Glabellar Lines
|
Phase 3 | |
| Completed |
NCT03736928 -
Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Glabellar Lines
|
Phase 2 | |
| Completed |
NCT01808742 -
Study Evaluating the Treatment of Forehead and/or Glabellar Lines With the CRYO-TOUCH III Device
|
N/A | |
| Completed |
NCT00430586 -
Finding of Optimal Dose for NT 201 in the Treatment of Glabellar Frown Lines
|
Phase 2 | |
| Completed |
NCT04281095 -
A Comparative Study of Botulinum Neurotoxin Type A in Treatment of Moderate to Severe Glabellar Frown Lines
|
Phase 1/Phase 2 | |
| Completed |
NCT05146999 -
Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines
|
Phase 3 | |
| Completed |
NCT02428608 -
Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006
|
Phase 2 | |
| Completed |
NCT04143815 -
Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Glabellar Lines
|
Phase 2 | |
| Not yet recruiting |
NCT05305768 -
Xeomin Treatment of Glabellar Lines Using OLD Versus COLD
|
Early Phase 1 | |
| Completed |
NCT05364580 -
The Efficacy and Safety Study of Protoxin Versus Botox® in Subjects With Moderate to Severe Glabellar Lines
|
Phase 3 | |
| Completed |
NCT05320393 -
Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines
|
Phase 2 | |
| Completed |
NCT02677805 -
Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study II
|
Phase 3 | |
| Completed |
NCT01333397 -
Safety and Efficacy Study of Dysport RU and Glabellar Lines
|
Phase 2 |